Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation
- 1 May 2008
- journal article
- review article
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 12 (21), III-212
- https://doi.org/10.3310/hta12210
Abstract
Health Technology Assessment Volume: 12, Issue: 21, Published in May 2008Funding Information
- Health Technology Assessment Programme (05/22/01)
This publication has 55 references indexed in Scilit:
- Early termination of drug trialsBMJ, 2007
- The value of risk scoresHeart, 2006
- Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic reviewHeart, 2006
- Cost of cardiovascular diseases in the United KingdomHeart, 2006
- Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) StudyAmerican Heart Journal, 2005
- Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trialAmerican Heart Journal, 2005
- Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non–ST-segment elevation myocardial infarction: One-year results of the third randomized intervention trial of unstable angina (RITA-3)Journal of the American College of Cardiology, 2005
- Cascade genetic screening for familial hypercholesterolemiaClinical Genetics, 2004
- Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatinAmerican Heart Journal, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003